Marvel Biosciences Corp (MRVL) AI Stock Analysis

• Market Cap: C$8.12M
• Dividend Yield: N/A
• Average Volume (3M): 89.38K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.50
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: CA
• Employees: N/A
• Sector: Technology
• Sector Strength: 88
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 58,004,482
• 10 Day Avg. Volume: 75,294
• 30 Day Avg. Volume: 89,378
• PEG Ratio: 0.04
• Price to Book (P/B): -2.07
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -7.20
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: C$0.13 ▼(-4.29% Downside)

The score is weighed down primarily by weak financial performance (no revenue, persistent losses/cash burn, and negative equity). Technicals also remain bearish with the stock below major moving averages and negative MACD. A positive corporate event (substantial warrant exercises) provides some financing relief, but it is not enough to offset the core balance-sheet and cash-burn risks.

Positive Factors

Promising Research Developments

The promising results from MB-204 in Rett syndrome suggest potential for breakthrough treatments in neurological disorders, strengthening Marvel's R&D pipeline and market position.

Successful Funding Initiatives

Securing substantial funding through private placements enhances Marvel's financial stability and supports ongoing R&D efforts, crucial for long-term growth in the biotech sector.

Strategic Regulatory Pursuits

Seeking Orphan Drug Designation could expedite MB-204's development, offering market exclusivity and regulatory advantages, potentially boosting Marvel's competitive edge in rare disease therapies.

Negative Factors

Zero Revenue

The lack of revenue highlights challenges in monetizing biotech products, posing risks to financial sustainability and limiting operational flexibility.

High Financial Leverage

High leverage and negative equity suggest financial instability, increasing the risk of insolvency and limiting Marvel's ability to invest in growth opportunities.

Negative Cash Flow

Ongoing cash burn without operational cash generation capacity strains resources, necessitating continuous external financing to sustain operations.

Marvel Biosciences Corp Business Overview & Revenue Model

Company Description

Marvel Biosciences Corp. operates as a pre-clinical stage pharmaceutical development biotechnology company. It engages in the discovery and development of synthetic derivative compounds of known drugs that inhibit the A2a adenosine receptor. The company offers Nourianz (Istradefylline, KW-6002) and MB-204 an adenosine A2A receptor antagonist. It targets neurological diseases, such as Alzheimer's disease, depression and anxiety, and non-neurological conditions of cancer; and non-alcoholic steatohepatitis. Marvel Biosciences Corp. is headquartered in Calgary, Canada.

How the Company Makes Money

Marvel Biosciences Corp generates revenue through the development and commercialization of its pharmaceutical products. The company primarily earns money by out-licensing its drug candidates to larger pharmaceutical firms, which may involve upfront payments, milestone payments, and royalties on future sales. Additionally, Marvel Biosciences may engage in collaborative research and development partnerships with other biotech or pharmaceutical companies, providing another revenue stream. The company's financial performance is significantly influenced by the success of its clinical trials, regulatory approvals, and the establishment of strategic alliances.

Marvel Biosciences Corp Financial Statement Overview

Summary

Marvel Biosciences Corp faces significant financial challenges, characterized by zero revenue, negative net income, and high cash burn, typical of early-stage biotech firms. The balance sheet reflects high leverage and solvency concerns, while cash flow statements indicate dependence on external financing.

Income Statement

Marvel Biosciences Corp has consistently reported zero revenue, indicating a lack of sales or monetization of its biotech products. The company shows significant negative net income and gross profit margins due to high operational costs and no revenue stream, reflecting challenges in achieving profitability.

Balance Sheet

The company has a negative stockholders' equity, which is a concerning sign of financial health, indicating liabilities exceed assets. The debt-to-equity ratio is not meaningful due to negative equity, suggesting high financial leverage and potential solvency risks.

Cash Flow

Negative operating cash flows indicate substantial cash burn, typical for early-stage biotech firms. However, consistent financing inflows show some ability to secure funds. The absence of free cash flow growth highlights a lack of operational cash generation capacity.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-547.37K	0.00	-887.52K	-1.38M	-613.10K
EBITDA	-1.94M	-1.54M	-2.25M	-2.55M	-1.25M
Net Income	-2.21M	-1.65K	-2.29M	-2.55M	-3.04M
Balance Sheet
Total Assets	326.71K	491.31K	672.39K	913.54K	2.47M
Cash, Cash Equivalents and Short-Term Investments	128.85K	345.77K	556.62K	593.21K	2.39M
Total Debt	2.31M	1.71M	1.00M	0.00	0.00
Total Liabilities	4.33M	3.32M	2.39M	718.00K	112.48K
Stockholders Equity	-4.01M	-2.83M	-1.72M	195.54K	2.36M
Cash Flow
Free Cash Flow	-1.15M	-1.18M	-1.33M	-2.19M	-1.37M
Operating Cash Flow	-1.15M	-1.18M	-1.33M	-2.19M	-1.37M
Investing Cash Flow	0.00	0.00	0.00	0.00	381.57K
Financing Cash Flow	933.41K	968.64K	1.30M	394.00K	3.16M

Marvel Biosciences Corp Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.14
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MRVL, the sentiment is Negative. The current price of 0.14 is below the 20-day moving average (MA) of 0.15, below the 50-day MA of 0.17, and below the 200-day MA of 0.16, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 37.44 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:MRVL.

Marvel Biosciences Corp Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	61 Neutral	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%
APLI	45 Neutral	C$2.43M	-0.96	―	―	-58.01%	29.73%
MRVL	42 Neutral	C$8.12M	-3.11	―	―	―	―
AGN	42 Neutral	C$2.56M	-0.94	―	―	―	64.77%

Marvel Biosciences Corp Corporate Events

Marvel Biosciences Issues Deferred Share Units to Directors

Marvel Biosciences Corp. has announced the issuance of 35,697 deferred share units (DSUs) to its three independent directors as a substitute for cash payment of directors’ fees. These DSUs will vest by October 31, 2026, and will be settled upon the directors’ departure from the company. This move reflects Marvel’s strategic approach to managing its financial resources while aligning the interests of its directors with the company’s long-term goals. The announcement is significant as it showcases Marvel’s commitment to its financial strategy and governance, potentially impacting its market perception and stakeholder confidence.